Skip to main content
SpringerLink
Log in

Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1

  • Clinical Research
  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

The histopathology of papillary thyroid hyperplasia and papillary thyroid carcinoma is similar enough to cause a diagnostic dilemma in a few cases. Both lesions may have papillary fronds with fibrovascular cores, nuclear crowding, and nuclear anisocytosis. Formalin-fixed paraffin-embedded tissues from 30 randomly selected patients with papillary thyroid hyperplasia and an equal number from patients with papillary thyroid carcinoma were analyzed for expression of cytokeratin 19 (CK19), galectin-3, and HBME-1. Cases of papillary thyroid carcinoma had moderate to strong CK19, galectin-3, and HBME-1 reactivity although both CK19 and galectin-3 showed positive staining in a significant number of nonneoplastic thyroid cases. HBME-1 was uncommon in the nonneoplastic cases. These results indicate that HBME-1 may be useful in helping to distinguish papillary thyroid carcinoma from hyperplasia in diagnostically difficult cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. LiVolsi VA. Surgical pathology of the thyroid. vol. 5. Philadelphia: WB Saunders; 1990.

    Google Scholar 

  2. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland: atlas of tumor pathology, 3rd series, fascicle 5. Washington, DC: Armed Forces Institute of Pathology, 1992.

    Google Scholar 

  3. Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz SV, Lloyd RV. p27kipl expression distinghuishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Modern Pathol 13(9):1014–1019, 2000.

    Article  CAS  Google Scholar 

  4. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 Immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116:696–702, 2001.

    Article  CAS  PubMed  Google Scholar 

  5. Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Modern Pathol 7(3):295–300, 1994.

    CAS  Google Scholar 

  6. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Modern Pathol 14(4):338–342, 2001.

    Article  CAS  Google Scholar 

  7. Schelfhout LJDM, Van Muijen GNP, Fleuren GJ: Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular adenoma. Am J Clin Pathol 11:654–658, 1989.

    Google Scholar 

  8. Kragsterman B, Grimelius L, Walin G, Werga P, Johansson H. Cytokeratin 19 expression in papillary thyroid carcinoma. Appl Immunohistochem Mol Morphol 7:181–185, 1999.

    CAS  Google Scholar 

  9. Miettinen M, Franscila K, Lehto V-P, Paasivuo R, Virtanen I. Expression of intermediate filament proteins in thyroid gland and thyroid tumors. Lab Invest 50:262–270, 1984.

    CAS  PubMed  Google Scholar 

  10. Chiariotti L, Berlingieri MT, De Rosa P, Battaglia C, Berger N, Bruni CB, Fusco A. Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 7(12):2507–2511, 1992.

    CAS  PubMed  Google Scholar 

  11. Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA. Interpretation of RET immuno-staining in follicular lesions of the thyroid. Am J Clin Pathol 118:186–193, 2002.

    Article  PubMed  Google Scholar 

  12. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors: potential diagnostic implications. Am J Pathol 147:815–822, 1995.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644–1650. 2001.

    Article  CAS  PubMed  Google Scholar 

  14. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronova V, Sanjuan X, Cardesa A, Liu F-T, Sobel ME. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 181:80–86, 1997.

    Article  CAS  PubMed  Google Scholar 

  15. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Kazusada S, Natsugoe S, Kazunobu S, Aikou T, Sato E. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31:428–433, 2000.

    Article  CAS  PubMed  Google Scholar 

  16. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termina A, Cappia S, De Giuli P, Angeli A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58(14):3015–3020, 1998.

    CAS  PubMed  Google Scholar 

  17. Miettinen M, Kovatich AJ. HBME-1: a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 3:115–122, 1995.

    Google Scholar 

  18. Sack MJ, Astengo-Osuna C, Bryan T.-Y.Lin, Battifora H, LiVolsi VA. HBME-1 immuno-staining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Modern Pathol 10(7):668–674, 1997.

    CAS  Google Scholar 

  19. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumors: preferential reactivity with malignant tumors. Virchows Arch 429:213–219, 1996.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Hilton 11, Mayo Foundation, Rochester, MN

    Mary B. Casey MD & Ricardo V. Lloyd MD, PhD

  2. Department of Helth Sciences Research (CML), Mayo Clinic and Mayo Foundation, Hilton 11, Rochester, MN

    Christine M. Lohse BS

Authors
  1. Mary B. Casey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine M. Lohse BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ricardo V. Lloyd MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary B. Casey MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casey, M.B., Lohse, C.M. & Lloyd, R.V. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 14, 55–60 (2003). https://doi.org/10.1385/EP:14:1:55

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1385/EP:14:1:55

Key words

Search

Navigation